期刊文献+

奥沙利铂联合化疗治疗结肠癌的疗效分析 被引量:8

Analysis of Therapeutic Effect of L-OHP Combined with Chemotherapy in the Treatment of Colon Carcinoma
下载PDF
导出
摘要 目的探讨奥沙利铂(L-OHP)联合化疗对晚期结肠癌的疗效和安全性及对血清肿瘤坏死因子α(TNF-α)、白细胞介素(IL)2水平的影响。方法将2008年3月至2013年8月崇阳县中医院收治的83例晚期结肠癌患者采用随机数字表法分为两组:对照组(43例)采用亚叶酸钙+5氟尿嘧啶进行化疗,观察组(40例)在对照组的基础上加用L-OHP治疗。治疗结束后,观察两组患者的疗效、不良反应及血清TNF-α、IL-2水平的变化情况。结果观察组化疗方案的总有效率显著优于对照组(P=0.013);两组不良反应发生率比较差异均无统计学意义(P>0.05);治疗后,两组患者的血清TNF-α水平均显著下降(P<0.01),且观察组下降幅度大于对照组(P<0.01),两组患者的IL-2水平均显著升高(P<0.01),且观察组上升降幅度大于对照组(P<0.01)。结论在晚期结肠癌的治疗中,采用L-OHP联合亚叶酸钙、氟尿嘧啶化疗,可以提高疗效,改善患者生存质量,值得临床运用。 Objective To investigate the therapeutic efficacy and safety of L-OHP + 5-FL/CF combined therapy for colon carcinoma,and the influence on the level of TNF-α,IL-2 in serum.Methods A total of 83 patients with advanced stage colon carcinoma admitted to Chongyang County Hospital of Traditional Chinese Medicine from Mar.2008 to Aug.2013 were randomly divided into treatment group of 40 cases and control group of 43 cases by random-number table.The control group was treated by 5-FL/CF,and the observation group was treated by the combined therpay of L-OHP + 5-FL/CF.The total effective rate,incidence of adverse reactions and TNF-α,IL-2 in serum of the two groups were compared.Results The total effective rate of the observation group was significantly better than the control group(P =0.013).The incidence of adverse reactions of the two groups were not statisticcally significantly different(P 〉 0.05) ; after treatment,serum TNF-α level in patients of the two groups were both significantly decreased(P 〈 0.01),and the observation group was much lower than the control group(P 〈 0.01),IL-2 of both groups were significantly increased(P 〈 0.01),and the observation group increase amplitude was significantly larger than the control group(P 〈 0.01).Conclusion The therapeutic efficacy of combined L-OHP + 5-FL/CF for colon carcinoma of advance stage is improved,which can improve the quality of life of the patients,and thus is worthy of application in clinical.
作者 徐匹夫
出处 《医学综述》 2014年第10期1883-1885,共3页 Medical Recapitulate
关键词 晚期结肠癌 亚叶酸钙 氟脲嘧啶 奥沙利铂 白细胞介素2 Advanced stage colon carcinoma Calcium folinate Fluorouracil Oxaliplatin Interleukin-2
  • 相关文献

参考文献12

  • 1徐瑞华,邱妙珍.晚期结直肠癌化疗的研究进展[J].癌症,2008,27(6):661-666. 被引量:51
  • 2邱妙珍,滕开原,阮丹云,李宇红,陈晓勤,潘志忠,何友兼,万德森,徐瑞华.术后辅助化疗时间对Ⅲ期和高危Ⅱ期结直肠癌3年无病生存期的影响[J].癌症,2009,28(7):743-748. 被引量:6
  • 3Sato S,Itamochi H,Kigawa J,et al.Combination chemotherapy of oxaliplatin and 5-fluorouracilmay be an effective regimen formucinous adenocarcinoma of the ovary:a potential treatment strategy[J].Cancer Sci,2009,100(3):546-551.
  • 4Hardy D,Cormier JN,Xing Y,et al.Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancee[J].J Thorac Oncol,2010,5(1):90-98.
  • 5胡远强,张永波,李欣,熊刚,罗爱华.奥沙利铂联合化疗治疗晚期结肠癌的近期疗效及安全性观察[J].中国药房,2011,22(4):331-332. 被引量:8
  • 6Teh J,Yap SP,Tham I,et al.Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma:survival outcomes,patterns of failure,and prognostic factors[J].Int J Gynecol Cancer,2010,20(3):428-433.
  • 7胡达水.奥沙利铂联合亚叶酸钙及氟尿嘧啶治疗晚期大肠癌的临床分析[J].中国医药科学,2012,2(9):78-79. 被引量:6
  • 8Tewari KS,Monk BJ.The rationale for the use of non-platinun chemotherapy doublets for metastatic and recurrent cervical carcinoma[J].Clin Adv Hematol Onco1,2010,8(2):108-115.
  • 9Sileri P,Dugo S,Bennavoli D,et al.Metachronous splenicmetastasis from colonic carcinoma five years after surgery:a case report and literature review[J].South Med J,2009,102(7):733-735.
  • 10Wu CH,Fan WC,Chen YM,et al.Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients[J].J Thorac Oncol,2010,5(3):376-379.

二级参考文献59

  • 1周建凤,陈书长.FOLFOX4方案一线治疗晚期大肠癌近期疗效分析[J].癌症进展,2006,4(5):452-455. 被引量:6
  • 2Gill S,Loprinzi CL,Sargent DJ,et al.Pooled analysis of fluorouracil-baeed adjuvant therapy for stage Ⅱ and Ⅲ colon cancer:who benefits and by how much?[J].J Clin Oncol,2004,22(10):1797-1806.
  • 3Benson AB 3rd,Schrag D,Somerfield MR,et al.American Society of Clinical Oncelogy recommendations on adjuvant chemotherapy for stage Ⅲ colon cancer[J].J Clin Oncol,2004,22(16):3408-3419.
  • 4Compton CC,Fielding LP,Burgart LJ,et al.Prognostic factors in colorectal cancer.College of American Pathologists Consensus Statement 1999[J].Arch Pathol Lab Med,2000,124(7):979-994.
  • 5Extra JM,Espie M,Cairo F,et al.Phase Ⅰ study of oxaliplatin in patients with advanced cancer[J].Cancer Chemnther Pharmacol,1990,25(4):299-303.
  • 6Andre T,Boni C,Mouredji-Bardint L,et al.Oxaliplatin,fluorouracil,and leucovorin as adjuvant treatment for colon cancer[J].N Engl J Med,2004,350(23):2343.
  • 7QUASAR Collaborative Group,Gray R,Barnwell J,McConkey C,et al.Adjuvant chemotherapy versus observation in patients with colorectal cancer:a randomized study[J].Lancet,2007,370 (9604):2020-2029.
  • 8O'Connell MJ,Laurie JA,Kahn M,et al.Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer[J].J Clin Oncol,1998,16(1):295-300.
  • 9Saini A,Norman AR,Cunningham D,et al.Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in eolorectal cancer[J].Br J Cancer,2003,88(12):1859-1865.
  • 10Sargent D,Wieand S,Goldberg R,et al.3 Year DFS vs.5 year OS as an endpoint for adjuvant colon cancer studies:data from randomized trials.Rackville,Md.:Food and Drug Administration,November 2003.(Accessed May 10,2004,at.http://www.fda.gov/eder/drug/cancer_endpoints/Sargent/index.htm.).

共引文献64

同被引文献85

  • 1陈浮,朱海杭,王璐.卡培他滨联合奥沙利铂术前新辅助化疗治疗中晚期胃癌的疗效分析[J].实用癌症杂志,2014,29(1):53-55. 被引量:28
  • 2谭纯文,钟献,沈彦伟,袁瑛.奥沙利铂与西妥昔单抗联用的分子机制研究现状[J].肿瘤防治研究,2014,41(2):176-180. 被引量:4
  • 3杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1469
  • 4门可,李良寿.循证医学(三)——Meta分析[J].疑难病杂志,2005,4(1):58-61. 被引量:18
  • 5陈慰峰,金伯泉.医学免疫学[M].北京:人民卫生出版社,2006:51-53.
  • 6Miller P, Kypri K. Why we will not accept fund- ing from Drinkwise. Drug Alcohol Rev 2009; 28:324-326 [PMID: 19489993 DOI: 10.1097/ SMJ.0b013e3181a93c39].
  • 7Comella P, Gambardella A, Farris A, Maiorino L, Natale D, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S. A tailored regimen including capecitabine and oxaliplatin for treating elderly pa- tients with metastatic colorectal carcinoma South- ern Italy Cooperative Oncology Group trial 0108. Crit Rev Oncol Hematol 2005; 53:133-139 [PMID: 15661564 DOI: 10.1016/j.critrevonc.2004.10.008].
  • 8Kweekel DM, Antonini NF, Nortier JW, Punt CJ, Gelderblom H, Guchelaar HJ. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 2009; 101:357-362 [PMID: 19536092 DOI: 10.1038/sj.bjc.6605134].
  • 9Kweekel DM, Antonini NF, Nortier JW, et al. Explo- rative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair ar- ray[J].Br J Cancer,2009(101):357-362.
  • 10van Horssen R,T.H.T.,Eggermont AM.TNF-alpha in can- cer treatment: molecular insights,antitumor effects,and clinical utility[J].Oncologist, 2006, 11 (4) : 397-408.

引证文献8

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部